Alert detail

FDA Approval: HYMPAVZI (MARSTACIMAB-HNCQ) — Type 1 - New Molecular Entity

Policy ID: FDA-BLA761369Specialty: OncologyAdded: 6/11/2026Effective: October 11, 2024billing update

High

What changed

New injectable Hympavzi gains FDA approval.

Who’s affected: Oncology billing teams · Effective: October 11, 2024

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

View subscription plans Create a free account

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.